Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing safety, tolerability, pharmacokinetics and antiviral activity of GS-9669 in adults with chronic hepatitis C virus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-9669 (GS-9669)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED